Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Drug Discovery
Overview
Conditions
Intellectual Property
Research
R&D Pipeline
Cobroxin
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Research

Cobratoxin inhibits pain-evoked discharge of neurons in thalamic parafascicular nucleus in rats: Involvement of cholinergic and serotonergic systems

Toxicon

Volume 54/ Issue 4 (15 September 2009)

 

Alpha cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application

Critical Reviews™ in Immunology
Volume 27/ Issue 4 2007

 

Analgesic effects of receptin, a chemically modified cobratoxin from Thailand cobra venom

Neuroscience Bulletin
September 2006

 

Amelioration of acute and relapsing stages of the Experimental Allergic Encephalomyelitis by Cobra Toxins

Biomedical Sciences Instrumentation
June 2006

 

A long-form a-neurotoxin from cobra venom produces potent opioid-independent analgesia

Acta Pharmacologica Sinica
April 2006

 

A short-chain a-neurotoxin from Naja naja atra produces potent cholinergic-dependent analgesia

Neuroscience Bulletin
March 2006

 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
February 05, 2015
Nutra Pharma Announces Distribution of Nyloxin® to India


July 24, 2014
Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales


June 10, 2014
Nutra Pharma Announces Contracts for Nyloxin Television Commercials


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics